Idecabtagene vicleucel
RxNorm 2536430
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2536430 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: idecabtagene vicleucel.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
INPrescribable
Ingredient (IN):
Idecabtagene vicleucel
(Atom ID: 12623523)
PTPrescribable
Designated preferred name (PT):
Idecabtagene vicleucel
(Atom ID: 12665167)
FNPrescribable
Full form of descriptor (FN):
Idecabtagene vicleucel (substance)
(Atom ID: 12665168)
PTPrescribable
Designated preferred name (PT):
Idecabtagene vicleucel-containing product
(Atom ID: 12665171)
FNPrescribable
Full form of descriptor (FN):
Product containing idecabtagene vicleucel (medicinal product)
(Atom ID: 12665548)
Patient Education
Idecabtagene Vicleucel Injection
Idecabtagene vicleucel injection is used to treat certain types of multiple myeloma (a type of cancer of the bone marrow) in adults whose cancer has returned or is unresponsive to at least four other treatments. Idecabtagene vicleucel injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells.
[Learn More]
* Please review the disclaimer below.